NuPathe (PATH) to Cut Workforce 50%, Delay IND for NP202, Cut NP101 Spending
Tweet Send to a FriendGet Alerts PATH Hot Sheet
Trade PATH Now!
As previously reported, on September 25, 2012, NuPathe Inc. (Nasdaq: PATH) entered into a Securities Purchase Agreement with certain qualified institutional purchasers and individual investors pursuant to which the Company agreed to sell to the Investors units of the Company’s securities for an aggregate purchase price of $28 million. The closing of the Proposed Financing is subject to certain specified closing conditions. In connection with the Proposed Financing, the Company is undertaking certain cost containment measures in order to focus its expenditures on gaining FDA approval of NP101, securing commercial partners and select pre-launch activities. The cost containment measures include, among others:
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
- A 50% reduction in workforce;
- Reducing expenditures relating to commercialization activities for NP101 and the earlier stage product candidates;
- Delaying the filing of an Investigational New Drug application for NP202, the Company’s product candidate for the long-term treatment of schizophrenia and bipolar disorder, until a co-development partner is obtained; and
- The previously reported restructuring of the Company’s outstanding debt under its term loan facility.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wal-mart (WMT) Posts Q1 EPS of $1.14; U.S. Comps Down 1.4%; Guides Q2 EPS
- Hollsys (HOLI) Tops Q3 EPS by 1c; Lowers FY13 Outlook
- NuPathe, Inc. (PATH) Reports Q1 Loss of $0.68
Create E-mail Alert Related Categories
Corporate News, Equity Offerings, GuidanceLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

